Treatment of Sydenham Chorea
All patients with Sydenham chorea should receive immediate antibiotic treatment at first presentation, followed by long-term secondary antibiotic prophylaxis, with corticosteroids recommended for moderate to severe cases, and symptomatic agents reserved for those requiring additional movement control. 1
Antibiotic Management
Acute Treatment
- Initiate antibiotics immediately at first presentation, regardless of whether acute streptococcal infection is documented 1
- This addresses potential ongoing or subclinical Group A streptococcal infection
Long-Term Prophylaxis
- Follow international or local ARF guidelines for secondary prophylaxis duration 1
- Benzathine penicillin G is the standard prophylactic agent
- Antibiotic prophylaxis significantly reduces chorea recurrence rates (odds ratio 0.28 for relapse) 2
- For patients with recurrent disease, consider more frequent dosing intervals (e.g., every 3 weeks instead of 4 weeks) 3
- Implement pain reduction strategies for intramuscular injections to improve adherence 1
Critical caveat: Irregular antibiotic prophylaxis is a major risk factor for chorea recurrence 3
Immunotherapy
Corticosteroids (First-Line Immunotherapy)
Corticosteroids are recommended for moderate to severe Sydenham chorea 1
The evidence strongly supports corticosteroid use:
- Patients receiving ≥1 month of corticosteroids had median chorea duration of 1.2 months versus 2.8 months without treatment (p=0.004) 2
- Corticosteroids reduce relapse risk substantially (OR 0.32; patients on ≥1 month had OR 0.10 for relapse) 2
- Prednisolone shows promising results with weight gain as the primary side effect 4
Second-Line Immunotherapy
For patients with inadequate recovery after corticosteroids:
The evidence for these modalities is limited to small case series 5, but the 2025 consensus guidelines support their use in refractory cases 1
Symptomatic Treatment
When to Use Symptomatic Agents
Reserve symptomatic medications for:
- Patients requiring additional movement control beyond immunotherapy
- Those with severe functional impairment from chorea
- Bridging therapy while awaiting immunotherapy response
Dopamine Antagonists
- Haloperidol is the most commonly used dopamine antagonist 4
- Effective for chorea suppression but does not alter disease course
- Monitor for extrapyramidal side effects
Antiepileptic Drugs
- Valproic acid (sodium valproate) is the preferred antiepileptic 4
- Associated with reduced relapse risk (OR 0.33) 2
- May have dual benefit: symptomatic control plus disease-modifying effects
Important caveat: Symptomatic drugs alone were associated with higher relapse risk (p=0.045) compared to immunomodulatory therapy 6, reinforcing that they should not be used as monotherapy when immunotherapy is indicated.
Treatment Algorithm by Severity
Mild Cases
- Antibiotics (acute + prophylaxis)
- Consider observation if minimal functional impairment
- Add symptomatic agents only if needed
Moderate to Severe Cases
- Antibiotics (acute + prophylaxis)
- Corticosteroids (prednisolone) for ≥1 month 1, 2
- Add symptomatic agents (valproic acid or haloperidol) if additional control needed
- If inadequate response: IVIG or plasma exchange 1
Relapse Cases
- Repeat clinical assessment and etiological investigation 1
- Restart or intensify antibiotics
- Corticosteroid therapy should be considered 1
- Evaluate antibiotic prophylaxis adherence and consider more frequent dosing 3
Monitoring and Support
Clinical Monitoring
Screen for and address:
- Behavioral impairments (anxiety/depression in 77% of cases) 6
- Mobility limitations
- Swallowing difficulties
- Speech impairments
- Cognitive dysfunction
- Carditis (present in 81%, often subclinical) 6
Psychosocial Support
- Provide information and guidance to patients, families, and educators 1
- Minimize impact on academic and social functioning 1
- Neuropsychiatric symptoms persist beyond 12 months in 10% of patients 6
Key Pitfalls to Avoid
- Do not assume SC is benign and self-limiting - this outdated view leads to undertreatment 6
- Do not use symptomatic agents as monotherapy in moderate-severe cases - they increase relapse risk without immunotherapy 6
- Do not neglect cardiac evaluation - 81% have carditis, often subclinical 6
- Do not discontinue antibiotic prophylaxis prematurely - irregular use is a major relapse risk factor 3
- Do not delay immunotherapy in moderate-severe cases - earlier treatment shortens disease duration 2